Recently, multinational corporations (MNCs) have successively releasedQ2 2025 PerformanceFinancial Report,In terms of overall trends, the majorityQ2 Performance Rebound。Among them, Eli Lilly's quarterly revenue was $15.558 billion, compared to $11.303 billion in the same period last year, representing a year-on-year increase.38%. Net profit of 5.661 billion US dollars, compared to 2.967 billion US dollars in the same period last year, increased by91%AbbVie's quarterly revenue was $15.423 billion, compared to $14.462 billion in the same period last year, representing a year-over-year increase.6.6%Net profit of 938 million US dollars, compared to 1.37 billion US dollars in the same period last year.Johnson & JohnsonQuarterly revenue was US$23.743 billion, compared to US$22.447 billion in the same period last year, representing a year-on-year increase.5.8%. Net profit of 5.537 billion US dollars, compared to 4.686 billion US dollars in the same period last year, increased by18.2%。PfizerQuarterly revenue was $14.653 billion, compared to $13.283 billion in the same period last year, representing a year-over-year increase.10%Net profit of $2.91 billion, compared to $41 million in the same period last year.BMSQuarterly revenue was $12.269 billion, compared to $12.201 billion in the same period last year. Net profit was $1.31 billion, compared to $1.68 billion in the same period last year.Yuan.AmgenQuarterly revenue was $9.179 billion, compared to $8.388 billion in the same period last year. Net profit was $1.432 billion, compared to $746 million.Dollar.RegeneronQuarterly revenue was $3.676 billion, compared to $3.547 billion in the same period last year. Net profit was $1.392 billion, compared to $1.432 billion in the same period last year.In terms of specific fields,GLP-1 and Its DerivativesRemains the core force driving industry growth, metabolismThe competitive advantage in the field of weight management is rapidly translating into a continuous rise in revenue. Eli Lilly is a prime example, with itsThe driving factors remain in the metabolism and weight management sector,Mounjaro and Zepbound Form a "Dual-Engine" Pattern. At the same time, some MNCsRevenue from multiple core products has significantly declined, such as those under Johnson & Johnson.Stelara，After the patent expiration in 2024, biosimilars rapidly expanded in the U.S. and European markets, intensifying pricing wars, with Q2 revenue decreasing year-over-year.A sharp drop of 42.7%To $1.653 billion.AbbVieHumiraSince the patent expiration in 2023，Dual Pressures of Price and Market Share Lead to Q2 RevenuePlummeted by 58%To $11.80 billion.Most of these drugs are either nearing the end of their patent protection or have already lost their exclusive status, facing strong competition from biosimilars and next-generation therapies, or being significantly affected by fluctuations in single-market demand. They were once the cornerstone of corporate profits but now must confront the impact brought by the natural lifecycle. The effectiveness of a company’s strategic transformation will directly determine the severity and depth of this impact.·END· Previous ·Selected
